<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037101</url>
  </required_header>
  <id_info>
    <org_study_id>07-01-1896</org_study_id>
    <nct_id>NCT01037101</nct_id>
  </id_info>
  <brief_title>D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights</brief_title>
  <official_title>D-Cycloserine as Enhancer of One-Session Treatment for Phobia of Heights in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Charleston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CAMC Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the effects of D-Cycloserine (DCS) on fear reduction in patients
      diagnosed with phobia of heights (acrophobia) undergoing one session of three hours of
      virtual reality exposure therapy (VRET) or in vivo exposure therapy (IVET).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of D-Cycloserine on Virtual Reality Exposure Therapy (VRET) and In Vivo Exposure
      Therapy (IVET) for phobia of heights (acrophobia) will be tested using a randomized,
      double-blind, placebo-controlled trial. Eighty participants will be randomly assigned to one
      of the four treatment conditions: one-session VRET (3 hours) and 50 mg D-Cycloserine (VR-OST
      + DCS, N1=20); one-session VRET (3 hours) and placebo (VR-OST + Pl, N2=20); one-session IVET
      (3 hours) and placebo (IV + Pl, N3=20); or one-session IVET (3 hours) and 50 mg
      D-Cycloserine, (IV + DCS, N4=20). For twenty participants (5 from each group) the treatment
      will be delayed for three weeks and an additional assessment will be conducted as they will
      comprise a Wait List (WL) control group. Behavioral, cognitive and physiological changes in
      acrophobia will be assessed at pre-treatment, post-waitlist, post-treatment and 3 months
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specific Phobia (acrophobia) diagnosis based on Anxiety Disorders Interview Schedule-IV (ADIS-IV)</measure>
    <time_frame>One week post-treatment and 3 months folow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physiological responses to phobia-related stimuli, percentage of steps completed and Subjective Units of Distress during a Behavioral Avoidance Test (BAT)</measure>
    <time_frame>One week post-treatment and 3 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Height Phobia</condition>
  <arm_group>
    <arm_group_label>IVET+DCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VRET+DCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VRET+Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IVET+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-List</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>3 weeks Wait-List</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>In Vivo Exposure Therapy</intervention_name>
    <description>Three hours of exposure therapy in a high place</description>
    <arm_group_label>IVET+DCS</arm_group_label>
    <arm_group_label>IVET+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Virtual Reality Exposure Therapy</intervention_name>
    <description>Three hours of exposure therapy using a virtual reality system</description>
    <arm_group_label>VRET+DCS</arm_group_label>
    <arm_group_label>VRET+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-Cycloserine</intervention_name>
    <description>50 mg of DCS administered 30 minutes before the session</description>
    <arm_group_label>IVET+DCS</arm_group_label>
    <arm_group_label>VRET+DCS</arm_group_label>
    <other_name>Seromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg placebo administered 30 minutes before the session</description>
    <arm_group_label>VRET+Placebo</arm_group_label>
    <arm_group_label>IVET+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 65 years

          -  Men and women

          -  Diagnosis of acrophobia based on a clinical interview (ADIS-IV)

          -  Must sign an informed consent document after complete explanation of the study
             documenting that they understand the purpose of the study, procedures to be
             undertaken, possible benefits, potential risks, and are willing to participate.

        Exclusion Criteria:

          -  A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional
             disorders; organic brain syndrome, cognitive dysfunction that could interfere with
             capacity to engage in therapy;

          -  A history of substance or alcohol dependence (other than nicotine) in the last 6
             months or otherwise unable to commit to refraining from alcohol use during the period
             of study participation.

          -  Patients with significant suicidal ideation or who have enacted suicidal behaviors
             within 6 months prior to intake will be excluded from study participation and referred
             for appropriate services.

          -  Patients must be off concurrent anxiolytics and beta blockers and on a stable dose of
             antidepressant medication for at least 3 weeks prior to initiation of randomized
             treatment.

          -  Patients receiving medication that might interfere with study medication (medication
             that might lower seizure threshold: meperidine or antibiotics in high dosage:
             penicillins, cephalosporins, amphotericin and imipenem),

          -  Patients with a current or past history of seizures

          -  Pregnant women, lactating women, and women of childbearing potential who are not using
             medically accepted effective methods of contraception or abstinence

          -  Patients with a history of renal insufficiency (creatinine clearance less than 60
             mL/min) or liver insufficiency

          -  Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing
             psychotherapy of any duration specifically targeting phobias

          -  Patients unable to understand study procedures and participate in the informed consent
             process.

          -  Other serious medical illnesses (e.g., cardiovascular, liver, kidney, respiratory,
             endocrine, neurologic, or blood-related diseases),

          -  Inability to tolerate wearing the Virtual Reality Head Mounted Display,

          -  If patients refuse the study medication

          -  Any allergic reactions to D-Cycloserine by history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristian Sirbu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMC Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Virginia University School of Medicine Charleston Division</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristian Sirbu, Ph.D.</last_name>
      <phone>304-388-1024</phone>
      <email>cristian.sirbu@camc.org</email>
    </contact>
    <contact_backup>
      <last_name>Patrick L Kerr, Ph.D.</last_name>
      <phone>304.388.1033</phone>
      <email>patrick.kerr@camc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CAMC Health System</investigator_affiliation>
    <investigator_full_name>Crisitian Sirbu, PhD</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>acrophobia</keyword>
  <keyword>virtual reality</keyword>
  <keyword>exposure therapy</keyword>
  <keyword>In Vivo Exposure Therapy plus D-Cycloserine</keyword>
  <keyword>In Vivo Exposure Therapy plus Placebo</keyword>
  <keyword>Virtual Reality Exposure Therapy plus D-Cycloserine</keyword>
  <keyword>Virtual Reality Exposure Therapy plus Placebo</keyword>
  <keyword>Wait-List</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

